AR and prostate neoplasm: In agreement with the TFEA results, analyzing specific publicly available AR-ChIP-seq data from human prostate tumors and normal tissues revealed that 48% of our DE-lncRNAs contained at least one tumor-specific AR-binding site within their regulatory regions, while this percentage was smaller for normal prostate-specific ARBS (22%).